PL1, JNJ-63733657, JNJ-63733657, florquinitau F18 clinical trials

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease

This study is testing a new medicine, JNJ-63733657, for people with early Alzheimer's disease. Researchers want to see if it's safe and helps improve memory and thinking over two years, compared to a dummy drug.